Metorthrit (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This action suppresses rapidly dividing cells, including immune cells that drive inflammation and cancer cells that proliferate uncontrollably.

The specific dose of Metorthrit is determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and treatment response. Dosing regimens vary widely and should follow the prescriber’s written order.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and loss. It is also excreted in breast milk, so breastfeeding is not recommended while receiving the drug.

To request Metorthrit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with biologic DMARDs, methotrexate (Metorthrit) is a small‑molecule agent that is generally less expensive and administered by injection or orally. It has a well‑established efficacy profile but requires regular laboratory monitoring for hepatic and hematologic safety, whereas biologics target specific cytokines with different risk profiles.

Metorthrit should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discolored or contains particles.

Metorthrit is supplied as an injectable solution and can be given intramuscularly, intravenously or subcutaneously according to the prescriber’s instructions. Administration should be performed by a qualified healthcare professional using aseptic technique.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, acute renal failure, and rare but severe pancytopenia. Patients should be monitored closely for signs of organ dysfunction and infection throughout therapy.

Metorthrit is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate, and those receiving live vaccines. Caution is also advised for patients with pre‑existing blood disorders or uncontrolled infections.